

National Institute for Health and Clinical Excellence

IP952 - Partial replacement of the meniscus of the knee using a biodegradable scaffold.

Consultation Comments table

IPAC date: Thursday 10th May

Com. no.	Consultee name and organisation	Sec. no.	Comments	Response Please respond to all comments
1	Consultee 1 Specialist Adviser	1	Happy wiyh this. good clinical follow-up essential	Thank you for your comment.
2	Consultee 1 Specialist Adviser	2.1	happy with this	Thank you for your comment.
3	Consultee 1 Specialist Adviser	2.2	happy with this	Thank you for your comment.
4	Consultee 1 Specialist Adviser	2.3	no further comments.clinical follow-up must include all the key efficacy outcomes as described above	Thank you for your comment.
5	Consultee 1 Specialist Adviser	2.4	nothing further to add	Thank you for your comment.
6	Consultee 1 Specialist Adviser	2.5	patient selection will vary from surgeon to surgeon.Patients should be symptomatic. there is no indication to operate on the asymptomatic patient.	Thank you for your comment.

Com. no.	Consultee name and organisation	Sec. no.	Comments	Response
7	Consultee 2 Manufacturer Orteq Ltd	General	<p>Many thanks for your phone call last week and your kind help. As discussed please find attached the following manuscripts for the panels review:</p> <ul style="list-style-type: none"> • Verdonk et al 2011 -Tissue Ingrowth After Implantation of a Novel, Biodegradable Polyurethane Scaffold for Treatment of Partial Meniscal Lesions • Verdonk et al 2012 -Successful Treatment of Painful Irreparable Partial Meniscal Defects With a Polyurethane Scaffold • Spencer, Spalding 2012 - Meniscal scaffolds: Early experience and review of the literature • Efe, Getgood 2011 - The safety and short-term efficacy of a novel polyurethane • Seibold 2011 - Partial Meniscus Substitution with Tissue- Engineered Scaffold: An Overview • Zaffagnini 2012 AAOS abstract • Mouzopoulos G, 2012- Partial meniscus substitution with tissue-engineered scaffold: an overview <p>May I please submit an additional paper to you please (attached) for the consideration of the panel.</p> <ul style="list-style-type: none"> • Gomoll et al - Surgical treatment for early osteoarthritis. Part II: allografts and concurrent procedures 	<p>Please respond to all comments</p> <p>Thank you for your comment.</p> <p>Two papers cited by the consultee (Spencer 2012; Verdonk 2012) have been added to the main extraction table (table 2) of the overview. Five papers cited by the consultee (Efe 2011 Gomoll 2012; Mouzopoulos 2012; Seibold 2011 Zaffagnini 2012) have been added to Appendix A of the overview. The Verdonk (2011) paper which was included in the main extraction table has now been added to Appendix A as this is an interim report of Verdonk (2012).</p>

Com. no.	Consultee name and organisation	Sec. no.	Comments	Response
8	Consultee 2 Manufacturer Orteq Ltd	General	<p>Also we have several publically available videos (links below) that give some patient perspective to the use of [REDACTED] as well as some expert insight. I hope these are of interest and use to the panel.</p> <p>http://www.youtube.com/watch?feature=player_embedded&v=oh3RFTNQjTs [REDACTED] animation</p> <p>http://www.youtube.com/watch?v=S7mSc86Gpng&feature=player_embedded [REDACTED] patient interview [REDACTED]</p> <p>http://www.youtube.com/watch?v=ASPGoRDvFQk&feature=player_embedded [REDACTED] patient interview [REDACTED]</p> <p>http://www.youtube.com/watch?v=Q5xmNJNw99w&feature=player_embedded [REDACTED] patient interview [REDACTED]</p> <p>http://www.youtube.com/watch?feature=player_embedded&v=QJbRWdaBQ_Q [REDACTED] patient interview [REDACTED]</p> <p>http://www.youtube.com/watch?feature=player_embedded&v=lFE90dyWFQ Interview with Professor Rene Verdonk</p>	<p>Please respond to all comments</p> <p>Thank you for your comment.</p> <p>Statements made on social networking websites cannot be considered as evidence in the Interventional Procedures Programme.</p>

"Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees."